Komori
Eisai (4523) · InitiativeFirst stated

Phase III trial of EA8001 in schizophrenia

First written in FY2026. 1 of 3 entries say "Restated". Latest entry: FY2026.

3entries
1years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst stated2026-05-15 – FY20262026: 32026
Same theme, other companies
EA8001 Phase III Trial for SchizophreniaA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「「EA8001」（一般名：evenamide）について、日本において、EAファーマ株式会社が抗精神病薬2剤以上に対して不応又は効果不十分な統合失調症を対象としたフェーズⅢ試験を開始し、実施中です。」

    EA8001について、既存抗精神病薬2剤以上に不応または効果不十分な統合失調症を対象とする日本のフェーズⅢ試験開始を初めて記載した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Eisai yet. It last moved in the General Meetings of Shareholders of 2026-05-16: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Phase III trial of EA8001 in schizophrenia | Eisai Co.,Ltd. (4523) | Komori